CagriSema (Cagrilintide B and Semaglutide I)

DRUG4 trials

Sponsors

Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2Diabetic Peripheral NeuropathyObesity

Phase 1

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesity

CompletedNCT06716307

Novo Nordisk A/SObesity

Start: 2024-12-02End: 2025-03-28Updated: 2026-08-31

Phase 2

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

CompletedNCT06797869

Novo Nordisk A/SDiabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy

Start: 2025-01-29End: 2026-08-05Updated: 2026-09-10

Phase 3

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

Active, not recruitingNCT07011667

Novo Nordisk A/SObesity

Start: 2025-06-03End: 2028-10-17Updated: 2026-07-24

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

RecruitingNCT07282613

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2026-08-04End: 2030-03-30Target: 80Updated: 2026-09-09